Table 1.
Prospective clinical trials evaluating PD-1/PD-L1 blockades combining with RT in NSCLC.
| Trial | Phase | Stage | N | sequence | ICI Agent | RT Dose | OS | PFS | Toxicity≥G3(%) |
|---|---|---|---|---|---|---|---|---|---|
| PACIFIC (49, 50) | III | Locally advanced Unresectable III | 713 | CRT> ICI vs. CRT>placebo | Durvalumab (10 mg per kilogram of body weight intravenously every 2 weeks) | 54-66Gy | 1-yr: 83.1% vs.74.6% | Median 17.2 vs. 5.6 months | 30.5% vs. 26.1% |
| 2-yr: 66.3% vs. 55.3% | |||||||||
| HCRN LUN 14 -179 (51) | II | Locally advanced Unresectable IIIA/B | 92 | CRT> ICI | Pembrolizumab (200 mg intravenously every 3 weeks) | 59.4-66.6Gy | 1-yr: 81.2% | Median 18.7months | 4.30% |
| 2-yr: 62.0% | |||||||||
| 3-yr: 48.5% | |||||||||
| DETERRED (52) | II | Locally advanced Unresectable III | 40 | CRT+ICI>CT+ICI vs. CRT>CT+ICI | atezolizumab (1200 mg IV Q3 weeks) | 60-66Gy/30-33 fractions | 1-yr: 60% vs. 77% | Median 20.1 months vs. NR 1-yr:60% vs. 66% | 57% |
| ETOP NICOLAS (53) | II | Locally advanced Unresectable IIIA/B | 79 | CRT+ICI> ICI | Nivolumab (360 mg every three weeks for the first four doses, followed by 480 mg every four weeks) | 66 Gy/33fractions | NR | NR | 10% for pneumonitis |
| PEMBRO -RT (42) | II | metastatic IV | 74 | SBRT (single tumor site)> ICI vs. ICI | Pembrolizumab (200mg every three weeks) | 24Gy/3fractions | Median 15.9 vs. 7.6months | Median 6.6 vs. 1.9months | 17% vs. 22% |
RT, radiotherapy; CRT, chemoradiotherapy; CT, chemotherapy; SBRT, stereotactic body radiotherapy; ICI, immune checkpoint inhibitors; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; NR, not reported.